Litigation Details for Bausch Health Ireland Limited v. Lupin Ltd. (D. Del. 2019)
✉ Email this page to a colleague
Bausch Health Ireland Limited v. Lupin Ltd. (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-04-03 |
| Court | District Court, D. Delaware | Date Terminated | 2019-08-05 |
| Cause | Assigned To | Colm Felix Connolly | |
| Jury Demand | Referred To | ||
| Patents | 10,016,504; 8,999,313; 9,326,969; 9,592,252; 9,707,297 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Bausch Health Ireland Limited v. Lupin Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Bausch Health Ireland Limited v. Lupin Ltd. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-04-04 | 1 | Complaint | (“the ʼ252 patent”); 9,707,297 B2 (“the ʼ297 patent”); and 10,016,504 B2 (“the ʼ504 patent”) arising …United States Patent Nos. 8,999,313 B2 (“the ʼ313 patent”); 9,326,969 B2 (“the ʼ969 patent”); 9,592,252…the ’313 patent; claims 1–9 of the ’252 patent; claims 1–6, 8–18, and 20–24 of the ’297 patent; and claims… THE PATENTS IN SUIT 29. The U.S. Patent and Trademark Office (“PTO…PTO”) issued the ’313 patent on April 7, 2015. The ’313 patent claims, inter alia, compositions for admixture | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
